Drug Profile
SC 005
Alternative Names: SC005Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator AbbVie
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for phase-I development in Triple negative Breast-cancer(In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in USA (IV)
- 05 Oct 2018 AbbVie terminates a phase I trial in Triple negative Breast cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, In adults, In the elderly) in USA due to strategic considerations (IV) (NCT03316794)
- 08 Jan 2018 Phase-I clinical trials in Triple negative Breast cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, In adults, In the elderly) in USA (IV) (NCT03316794)